Raleigh, NC, United States of America

Andreas Spaltenstein


Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 1997-2001

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Andreas Spaltenstein: Innovator in Pharmaceutical Compounds

Introduction: Andreas Spaltenstein, a visionary inventor based in Raleigh, NC, has made significant contributions to the field of pharmaceuticals. With a robust portfolio of two patents, he focuses on advancing drug development and therapeutic solutions. His work has the potential to revolutionize treatment methodologies in the healthcare sector.

Latest Patents: Among Andreas's latest inventions are groundbreaking patents dealing with pharmaceutical compounds and neuropeptide Y antagonists. The pharmaceutical compounds patent provides a compound formula that offers new avenues for medicinal applications. Meanwhile, his research on neuropeptide Y antagonists explores innovative approaches to treating various health conditions.

Career Highlights: Currently, Andreas is associated with Glaxo Wellcome Inc., where he leverages his expertise to drive forward-thinking projects in drug discovery and development. His two patents signify not just personal milestones but also reflect his commitment to enhancing pharmaceutical science.

Collaborations: Throughout his career, Andreas has collaborated with notable coworkers Johann Jakob Leban and Douglas Byron Sherman. These partnerships have enriched his research projects and contributed to collective advancements in their respective fields.

Conclusion: Andreas Spaltenstein stands out as an influential inventor in the pharmaceutical industry. His contributions through patents are poised to impact future research and innovation consistently. With a strong dedication to improving healthcare solutions, he continues to inspire and lead in the quest for new therapeutic alternatives.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…